J7Z Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Raised GuidanceRecord quarterly revenue and higher full-year guidance indicate broad commercial momentum across Jazz’s portfolio. Growth in oncology, Xywav, Epidiolex and Zepzelca supports revenue durability, while the diversified product base reduces reliance on a single near-term growth driver.
Resilient Cash Generation And Improved LeverageConsistently positive operating and free cash flow gives Jazz capacity to fund clinical development, acquisitions and debt obligations internally. The combination of stronger cash generation and materially lower leverage improves financial flexibility and supports investment in future growth.
Pipeline And Oncology ExpansionExpansion into first-line HER2-positive gastroesophageal cancer and rare epilepsy strengthens Jazz’s long-term portfolio beyond its established sleep medicines. Ziihera adds commercial oncology opportunity, while ABS-1230 increases pipeline depth in a specialized neurological market.
Bears Say
Ongoing Competitive And Generic RiskThe oxybate franchise remains exposed to generic competition and emerging orexin treatments, which could pressure patient growth, pricing and market share over time. Even with limited generic uptake so far, these threats may reduce the durability of a key revenue and cash-flow contributor.
Margin Pressure From Royalties And InvestmentHigher royalty-bearing product sales and increased commercial and research spending are weighing on margins. These costs may be strategically justified by oncology launches and pipeline development, but sustained expense growth could limit operating leverage and temper profit expansion.
Historically Uneven ProfitabilityThe recent profitability rebound is encouraging, but repeated historical losses show that earnings have not been consistently stable. Such volatility can make long-term profit planning more difficult and leaves results sensitive to product performance, development spending and one-time charges.
Jazz Pharmaceuticals News
J7Z FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is CHF12.76B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 35 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported CHF4.756 earnings per share for the quarter, missing the consensus estimate of CHF5.144 by -CHF0.387.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 5.37.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 64,914,570 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of CHF4.756 in its last earnings report, missing expectations of CHF5.144. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:J7Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF247.53 (― Upside)
CHF247.53 (― Upside)
Blogger Sentiment
Bullish
CH:J7Z Sentiment 78%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
J7Z Company Deck
J7Z Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and pipeline wins — record revenue, raised guidance, double-digit growth across key brands (oncology +32%, Xywav +13%, Epidiolex +16%, Zepzelca +42%) and a solid balance sheet — while acknowledging manageable margin pressure from royalties, rising SG&A/R&D investments, label adjustments for Zepzelca second-line, and potential future competitive/generic risks for the oxybate franchise. On balance, the positive execution, guidance raise, cash generation and late-stage regulatory momentum outweigh the identified challenges.View all CH:J7Z earnings summariesJ7Z Stock 12 Month Forecast
Average Price Target
―Neurocrine
―
Xenon
―
Axsome Therapeutics
―
Harmony Biosciences Holdings
―
Praxis Precision Medicines
―